ArticleBMC gastroenterology2025
Integrated structural and functional brain imaging reveals biomarkers of disease activity in Crohn's disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThe brain’s response to intestinal inflammation in Crohn’s disease (CD) remains poorly characterized. We aimed to identify a neuroimaging signature of disease activity by integrating structural and functional brain metrics with machine learning.
methodsWe analyzed data from 235 participants across two cohorts: a primary cohort of 180 individuals (75 healthy controls [HCs], 70 CD in remission [CDR], 35 active CD [CDA]) for model development, and an independent validation cohort of 55 CD patients (16 CDA, 39 CDR). All participants underwent 3D T1-weighted and resting-state functional MRI. We performed voxel-based morphometry and seed-based functional connectivity (FC) analyses. A machine-learning pipeline combining Lasso regression and support vector machine was used to select features and construct a classifier to distinguish CDA from CDR.
resultsPatients with CD exhibited widespread brain alterations compared to HCs. Critically, the gray matter volume (GMV) of the right inferior frontal gyrus (opercular part extending to the triangular part; rIFGoper) was significantly higher in CDA than in CDR and was positively correlated with fecal calprotectin levels. FC of the rIFGoper and bilateral putamen with the default mode and sensorimotor networks was diminished in CD and correlated with clinical disease activity. A classifier built on 10 key imaging features (including rIFGoper GMV) differentiated CDA from CDR with an area under the curve (AUC) of 0.85 in the internal test set and 0.73 in an independent external set.
conclusionsWe identified a distinct neuroimaging signature of active CD, characterized by structural enlargement of the rIFGoper alongside characteristic network dysconnectivity. This signature, which correlates with gut inflammation, demonstrates strong potential as an objective biomarker for stratifying disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.